Trials / Active Not Recruiting
Active Not RecruitingNCT03032406
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the feasibility of administering HCQ, EVE or the combination in patients who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydroxychloroquine | Hydroxychloroquine |
| DRUG | Everolimus | Everolimus |
Timeline
- Start date
- 2017-01-23
- Primary completion
- 2022-05-17
- Completion
- 2026-01-01
- First posted
- 2017-01-26
- Last updated
- 2025-07-22
- Results posted
- 2025-03-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03032406. Inclusion in this directory is not an endorsement.